_11_12_2026_12_34_58_437217.jpg?#)
Artelo Biosciences Provides Business Update and Reports 2026 Third Quarter Financial Results
Continued Progress Across Pipeline Supports Expanded Therapeutic OpportunitiesSOLANA BEACH, Calif., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, obesity, dermatologic, ophthalmic, and neurological conditions, today provided a business update and announced its financial and operational results fo
Continued Progress Across Pipeline Supports Expanded Therapeutic OpportunitiesSOLANA BEACH, Calif., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, obesity, dermatologic, ophthalmic, and neurological conditions, today provided a business update and announced its financial and operational results fo
What's Your Reaction?
